Loss of function mutations, or the deletion of ATRX has also been shown to sensitise neuroblastoma cell lines and PDXs to the current standard-of-care drug irinotecan, in combination with the PARP inhibitor olaparib [62]. This evidence concerns the gene ATRX and neuroblastoma.